Overview

Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

Status:
Not yet recruiting

Trial end date:
2028-03-30

Target enrollment:

Participant gender:

Summary

This study is a Phase 2 open label, single arm, adaptive multi-centre trial. Patients with early stage HER2-positive breast cancer will receive neoadjuvant treatment of trastuzumab deruxtecan (T-DXd) 5.4mg/kg intravenously every three weeks for up to six cycles.

Phase:

Phase 2

Details

Lead Sponsor:

Cancer Trials Ireland

Treatments:

Trastuzumab